Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

177

10.17650/1726-9776-2009-5-1-8-13

LECTURE

ЛЕКЦИЯ

ЛЕЧЕНИЕ РЕЦИДИВОВ ГЕРМИНОГЕННЫХ ОПУХОЛЕЙ У МУЖЧИН

Федянин

М. Ю.

Russian Federation

Отделение клинической фармакологии и химиотерапии

Трякин

А. А.

Russian Federation

Отделение клинической фармакологии и химиотерапии

Тюляндин

С. А.

Russian Federation

Отделение клинической фармакологии и химиотерапии

ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва

30032009

8133007201430072014

https://oncourology.abvpress.ru/oncur/article/view/177

Лечение рецидивов герминогенных опухолей у мужчин

1. Porcu P., Bhatia S., Sharma M.,Einhorn LH. Results of treatment afterrelapse from high-dose chemotherapy ingerm cell tumors. J Clin Oncol2000;18(6):1181—6.

Porcu P., Bhatia S., Sharma M.,Einhorn LH. Results of treatment afterrelapse from high-dose chemotherapy ingerm cell tumors. J Clin Oncol2000;18(6):1181—6.

2. Loehrer P.J., Gonin R., Nichols C.R. et al. Vinblastine plus ifosfamide plus cis-platin as initial salvage therapy in recurrentgerm cell tumor. J Clin Oncol1998;16:2500—4.

Loehrer P.J., Gonin R., Nichols C.R. et al. Vinblastine plus ifosfamide plus cis-platin as initial salvage therapy in recurrentgerm cell tumor. J Clin Oncol1998;16:2500—4.

3. Motzer R.J., Chou T.C., Schwartz L. et al. Paclitaxel in germ cell cancer. SeminOncol 1995;22:12—5.

Motzer R.J., Chou T.C., Schwartz L. et al. Paclitaxel in germ cell cancer. SeminOncol 1995;22:12—5.

4. Bokemeyer C., Beyer J., Metzner B. et al. Phase II study of paclitaxel in patientswith relapsed or cisplatin-refractory testic-ular cancer. Ann Oncol 1996;7(1):31—4.

Bokemeyer C., Beyer J., Metzner B. et al. Phase II study of paclitaxel in patientswith relapsed or cisplatin-refractory testic-ular cancer. Ann Oncol 1996;7(1):31—4.

5. Tjulandin S., Titov D., Breder V. et al.Paclitaxel and cisplatin as salvage treatmentin patients with non-seminomatous germcell tumour who failed to achieve a com-plete remission on induction chemothera-py. Clin Oncol (R Coll Radiol)1998;10(5):297—300.

Tjulandin S., Titov D., Breder V. et al.Paclitaxel and cisplatin as salvage treatmentin patients with non-seminomatous germcell tumour who failed to achieve a com-plete remission on induction chemothera-py. Clin Oncol (R Coll Radiol)1998;10(5):297—300.

6. Sandler A.B., Cristou A., Fox S. et al. A phase II trial of paclitaxel in refractorygerm cell tumors. Cancer 1998;82:1381—6

Sandler A.B., Cristou A., Fox S. et al. A phase II trial of paclitaxel in refractorygerm cell tumors. Cancer 1998;82:1381—6

7. Motzer R.J., Sheinfeld J., Mazumdar M. et al. Paclitaxel, ifosfamide,and cisplatin second-line therapy forpatients with relapsed testicular germ cellcancer. J Clin Oncol 2000;18(12):2413—8.

Motzer R.J., Sheinfeld J., Mazumdar M. et al. Paclitaxel, ifosfamide,and cisplatin second-line therapy forpatients with relapsed testicular germ cellcancer. J Clin Oncol 2000;18(12):2413—8.

8. Donadio A., Sheinfeld J., Bacik J. et al.Paclitaxel, ifosfamide and cisplatine (TIP):an effective second-line therapy for patients(pts) wiyh relapsed testicular germ celltumors (GCT). Proc ASCO 2003. Abstr1537.

Donadio A., Sheinfeld J., Bacik J. et al.Paclitaxel, ifosfamide and cisplatine (TIP):an effective second-line therapy for patients(pts) wiyh relapsed testicular germ celltumors (GCT). Proc ASCO 2003. Abstr1537.

9. Mead G.M., Cullen M.H., Huddart R.et al. A phase II trial of TIP (paclitaxel,ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy forpatients with metastatic germ cell cancer: amedical research council trial. Br J Cancer2005;93:178—84.

Mead G.M., Cullen M.H., Huddart R.et al. A phase II trial of TIP (paclitaxel,ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy forpatients with metastatic germ cell cancer: amedical research council trial. Br J Cancer2005;93:178—84.

10.

10. Bokemeyer C., Gerl A., Schцffski P. et al. Gemcitabine in patients with relapsedor cisplatin-refractory testicular cancer. JClin Oncol 1999;17(2):512.

Bokemeyer C., Gerl A., Schцffski P. et al. Gemcitabine in patients with relapsedor cisplatin-refractory testicular cancer. JClin Oncol 1999;17(2):512.

11.

11. Einhorn L.H., Michael J., Stender M.J., Williams S.D. Phase II trialof gemcitabine in refractory germ celltumors. J Clin Oncol 1999;17(2):509.

Einhorn L.H., Michael J., Stender M.J., Williams S.D. Phase II trialof gemcitabine in refractory germ celltumors. J Clin Oncol 1999;17(2):509.

12.

12. Hinton S., Catalano P., Einhorn L.H.et al. Phase II study of paclitaxel plus gem-citabine in refractory germ cell tumors(E9897): a trial of the Eastern CooperativeOncology Group. J Clin Oncol2002;20(7):1859—63.

Hinton S., Catalano P., Einhorn L.H.et al. Phase II study of paclitaxel plus gem-citabine in refractory germ cell tumors(E9897): a trial of the Eastern CooperativeOncology Group. J Clin Oncol2002;20(7):1859—63.

13.

13. Pizzocaro G., Nicolai N., Salvioni R.et al. Paclitaxel, cisplatin, gemcitabine(TGP) third line therapy in metastatic germcell tumors (GST) of the testis. ProcASCO, 2001. Abstr 773.

Pizzocaro G., Nicolai N., Salvioni R.et al. Paclitaxel, cisplatin, gemcitabine(TGP) third line therapy in metastatic germcell tumors (GST) of the testis. ProcASCO, 2001. Abstr 773.

14.

14. Dunn T.A., Schmoll H.J., Grunwald V.et al. Comparative cytotoxicity of oxali-platin and cisplatin in non-seminomatousgerm cell cancer cell lines. Invest NewDrugs 1997;15(2):109—14.

Dunn T.A., Schmoll H.J., Grunwald V.et al. Comparative cytotoxicity of oxali-platin and cisplatin in non-seminomatousgerm cell cancer cell lines. Invest NewDrugs 1997;15(2):109—14.

15.

15. Kollmannsberger C., Rick O., Derigs H.-G. et al. Activity of oxaliplatin inpatients with relapsed or cisplatin-refracto-ry germ cell cancer: a study of the GermanTesticular Cancer Study Group. J ClinOncol 2002;20(8):2031—7.

Kollmannsberger C., Rick O., Derigs H.-G. et al. Activity of oxaliplatin inpatients with relapsed or cisplatin-refracto-ry germ cell cancer: a study of the GermanTesticular Cancer Study Group. J ClinOncol 2002;20(8):2031—7.

16.

16. Soulie P., Garrino C., Bensmaine M.A.et al. Antitumoral activity ofoxaliplatin/cisplatin-based combinationtherapy in cisplatin-refractory germ cellcancer patients. J Cancer Res Clin Oncol1999;125(12):707—11.

Soulie P., Garrino C., Bensmaine M.A.et al. Antitumoral activity ofoxaliplatin/cisplatin-based combinationtherapy in cisplatin-refractory germ cellcancer patients. J Cancer Res Clin Oncol1999;125(12):707—11.

17.

17. Bokemeyer C., Beyer J., Metzner B. et al. Combination chemotherapy withgemcitabine/oxaliplatin in relapsed or cis-platin-refractory germ cell cancer (GCT).Proc ASCO, 2003. Abstr 1561.

Bokemeyer C., Beyer J., Metzner B. et al. Combination chemotherapy withgemcitabine/oxaliplatin in relapsed or cis-platin-refractory germ cell cancer (GCT).Proc ASCO, 2003. Abstr 1561.

18.

18. Pectasides M., Farmakis D.,Aravantinos G. et al Gemcitabine andoxaliplatin (GEMOX) in patients with cis-platin-refractory germ cell tumors: a phaseII study D. Ann Oncol 2004;15:493—7.

Pectasides M., Farmakis D.,Aravantinos G. et al Gemcitabine andoxaliplatin (GEMOX) in patients with cis-platin-refractory germ cell tumors: a phaseII study D. Ann Oncol 2004;15:493—7.

19.

19. Kollmannsberger C., Beyer J., Liersch R. et al. Combination chemothera-py with gemcitabine plus oxaliplatin inpatients with intensively pretreated orrefractory germ cell cancer: a study of theGerman Testicular Cancer Study Group. JClin Oncol 2004;22:108—14.

Kollmannsberger C., Beyer J., Liersch R. et al. Combination chemothera-py with gemcitabine plus oxaliplatin inpatients with intensively pretreated orrefractory germ cell cancer: a study of theGerman Testicular Cancer Study Group. JClin Oncol 2004;22:108—14.

20.

20. De Giorgi U., Rosti G., Papiani G. et al. Weekly gemcitabine, paclitaxel, oxali-platin combination chemotherapy inpatients with cisplatinrefractory germ celltumor: preliminary experience. Am J ClinOncol 2004;27:457—60.

De Giorgi U., Rosti G., Papiani G. et al. Weekly gemcitabine, paclitaxel, oxali-platin combination chemotherapy inpatients with cisplatinrefractory germ celltumor: preliminary experience. Am J ClinOncol 2004;27:457—60.

21.

21. Theodore C., Flechon A., Fizazi K. et al. A phase II multicenter study of oxali-platin (Ox) in combination with paclitaxel(Px) in patients (pts) who failed cisplatin(CDDP) based chemotherapy (CT) forgerm cell tumors (GCT). Proc ASCO2004;23:389. Abstr 4534.

Theodore C., Flechon A., Fizazi K. et al. A phase II multicenter study of oxali-platin (Ox) in combination with paclitaxel(Px) in patients (pts) who failed cisplatin(CDDP) based chemotherapy (CT) forgerm cell tumors (GCT). Proc ASCO2004;23:389. Abstr 4534.

22.

22. Miki T., Mizutani Y., Nonomura N. et al. Irinotecan plus cisplatin has substan-tial antitumor effect as salvage chemothera-py against germ cell tumors. Cancer2002;95(9):1879—85.

Miki T., Mizutani Y., Nonomura N. et al. Irinotecan plus cisplatin has substan-tial antitumor effect as salvage chemothera-py against germ cell tumors. Cancer2002;95(9):1879—85.

23.

23. Kollmannsberger C., Rick O.,Klaproth H. et al. Irinotecan in patientswith relapsed or cisplatin-refractory germcell cancer: a phase II study of the GermanTesticular Cancer Study Group. Br JCancer 2002;23;87(7):729—32.

Kollmannsberger C., Rick O.,Klaproth H. et al. Irinotecan in patientswith relapsed or cisplatin-refractory germcell cancer: a phase II study of the GermanTesticular Cancer Study Group. Br JCancer 2002;23;87(7):729—32.

24.

24. Raymond E., Faivre S., Woynarowski J.M. et al. Oxaliplatin: mech-anism of action and antineoplastic activity.Semin Oncol 1998;25:4—12.

Raymond E., Faivre S., Woynarowski J.M. et al. Oxaliplatin: mech-anism of action and antineoplastic activity.Semin Oncol 1998;25:4—12.

25.

25. Pectasidesa D., Pectasides M.,Farmakis D. et al. Oxaliplatin and irinote-can plus granulocyte-colony stimulatingfactor as third-line treatment in relapsed orcisplatin-refractory germ-cell tumorpatients: a phase II study. Eur Urol2004;46:216—21.

Pectasidesa D., Pectasides M.,Farmakis D. et al. Oxaliplatin and irinote-can plus granulocyte-colony stimulatingfactor as third-line treatment in relapsed orcisplatin-refractory germ-cell tumorpatients: a phase II study. Eur Urol2004;46:216—21.

26.

26. De Giorgi U., Rosti G., Aieta M. et al.Phase II study of oxaliplatin and gemc-itabine salvage chemotherapy in patientswith cisplatin-refractory nonseminomatousgerm cell tumor. Eur Urol 2006;50:1032—9.

De Giorgi U., Rosti G., Aieta M. et al.Phase II study of oxaliplatin and gemc-itabine salvage chemotherapy in patientswith cisplatin-refractory nonseminomatousgerm cell tumor. Eur Urol 2006;50:1032—9.

27.

27. McGlynn K.A., Devesa S.S., Graubard B.I., Castle P.E. Increasing inci-dence of testicular germ cell tumors amongblack men in the United States. J ClinOncol 2005;23:5757—61.

McGlynn K.A., Devesa S.S., Graubard B.I., Castle P.E. Increasing inci-dence of testicular germ cell tumors amongblack men in the United States. J ClinOncol 2005;23:5757—61.

28.

28. Ronnen E.A., Kondagunta G.V., Bacik J. et al. Incidence of late-relapsegerm cell tumor and outcome to salvagechemotherapy. J Clin Oncol2005;23:6999—7004.

Ronnen E.A., Kondagunta G.V., Bacik J. et al. Incidence of late-relapsegerm cell tumor and outcome to salvagechemotherapy. J Clin Oncol2005;23:6999—7004.

29.

29. Shahidi M., Norman A.R., Dearnaley D.P. et al. Late recurrence in1263 men with testicular germ cell tumors.Multivariate analysis of risk factors andimplications for management. Cancer2002;95:520—30.

Shahidi M., Norman A.R., Dearnaley D.P. et al. Late recurrence in1263 men with testicular germ cell tumors.Multivariate analysis of risk factors andimplications for management. Cancer2002;95:520—30.

30.

30. Oldenburg J., Alfsen G.C., WЊhre H.,Fossa S.D. Late recurrences of germ cellmalignancies: a population-based experi-ence over three decades. Br J Cancer2006;94:820—7.

Oldenburg J., Alfsen G.C., WЊhre H.,Fossa S.D. Late recurrences of germ cellmalignancies: a population-based experi-ence over three decades. Br J Cancer2006;94:820—7.

31.

31. Sharp D.S., Carver B.S., Eggener S.E.et al: Clinical outcome of patients managedfor late relapse of germ cell tumor. J ClinOncol 2006;24(suppl; abstr 4550):229.

Sharp D.S., Carver B.S., Eggener S.E.et al: Clinical outcome of patients managedfor late relapse of germ cell tumor. J ClinOncol 2006;24(suppl; abstr 4550):229.

32.

32. Gerl A., Clemm C., Schmeller N. etal. Late relapse of germ cell tumors aftercisplatin-based chemotherapy. Ann Oncol1997;8:41—7

Gerl A., Clemm C., Schmeller N. etal. Late relapse of germ cell tumors aftercisplatin-based chemotherapy. Ann Oncol1997;8:41—7